

CHAPTER 50-05-02
PRESCRIPTION DRUG MONITORING PROGRAM RULE

Section

50-05-02-01 Prescription Drug Monitoring Program Rule

50-05-02-01. Prescription drug monitoring program rule.

1. Every practitioner who prescribes a controlled substance in North Dakota shall register with the prescription drug monitoring program.
2.
 - a. When a practitioner determines that reported drugs will be prescribed to a patient for a period to exceed twelve weeks, the practitioner shall request a prescription drug monitoring program report for that patient and, at a minimum, at least semiannually thereafter.
 - b. This requirement does not apply to reported drugs prescribed to patients in a controlled setting in which the drugs are locked and administered to the patient, for example, admitted hospital or hospice patients, long-term care patients or group home residents.
3. In addition to those reports requested under subsection 2, practitioners shall request a prescription drug monitoring program report when it is documented in the prescribing practitioner's medical record for that patient that the patient exhibits signs associated with diversion or abuse, including:
 - a. Selling prescription drugs;
 - b. Forging or altering a prescription;
 - c. Stealing or borrowing reported drugs;
 - d. Taking more than the prescribed dosage of any reported drug;
 - e. Having a drug screen that indicates the presence of additional or illicit drugs;
 - f. Being arrested, convicted, or diverted by the criminal justice system for a drug-related offense;
 - g. Receiving reported drugs from providers not reported to the treating practitioner;
 - h. Having a law enforcement or health professional express concern about the patient's use of drugs.
 - i. Violating any prescribing agreement with the physician;
 - j. Frequently requests early refills of a reported drug for any reason;
 - k. Appears impaired or excessively sedated to the physician in any patient encounter; and
 - l. Has a history of drug abuse dependency.
4. A practitioner shall document the receipt and assessment of prescription drug monitoring program reports made under this rule.

History: Effective January 1, 2018; amended effective October 1, 2022.

General Authority: NDCC 19-03.5-09(2)

Law Implemented: NDCC 19-03.5-09(2)